Autoimmune Cytopenia and BcR Inhibitors

Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)

Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)

The investigators of the study propose a card of data collection, validated by the scientific council of the group FILO.

The data to be collected are entered on an e-CRF made available to the investigators on a secure site.

The main data collected are as follows

• anonymized demographic data
• Clinical and Biological Data of CLL at Diagnosis
• Previous treatments of LLC and CAI
• clinical and laboratory data at the time of initiation of BCRi treatment
• response to treatment with BCRi
• tolerance to BCRi treatment
• Progression under treatment with BCRi
• Recent news

Inclusion Criteria:

• Patient with CLL
• Active autoimmune cytopenia
• Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.

Exclusion Criteria:

• Other lymphoid hemopathy B
• Absence of documentation of the autoimmunity of cytopenia